- October 27, 2026 · 3:15 PM · Stream C: Biotech Strategy
How can biotech sponsors maintain agility while scaling global trials?
Small and emerging biotech sponsors face increasing pressure to maintain operational control while advancing complex clinical programs under investor, timeline, and regulatory scrutiny. Join Benjamin Raccanova, Head of Business Oversight, for an industry peer-driven deep dive into the outsourcing strategies and operating models that deliver results.
Drawing on his 20+ years’ experience guiding PSI’s pharma and emerging biotech clients and PSI’s operational expertise across pivotal Phase 2–3 trials in 58 countries, Benjamin will share how sponsors can better align outsourcing strategy, communication structures, and operational oversight to reduce execution risk while maintaining speed and agility.
Meet Benjamin at Booth #25
Reserve your meeting to continue the conversation after the session.
* indicates required fields
"*" indicates required fields
What you can expect to learn
Explore the key factors that influence execution quality for emerging biotech sponsors, including:
Navigating traditional and niche CRO models as an emerging biotech
Understanding the key differences between big pharma and biotech approaches to clinical trial execution and outsourcing strategy
Examining how niche and specialist vendors are addressing sponsor pain points with more tailored, flexible solutions
Identifying how sponsors and providers can better align expectations, communication models, and operational support for successful partnerships
Panelist
Benjamin Rocannova
Head of Business Oversight
PSI
Connect with PSI in Boston
PSI is a privately owned global contract research organization founded in 1995, supporting pivotal Phase 2–3 clinical trials with a 97% LPI on-time delivery rate. Visit Booth #25 to discuss how PSI can help you balance agility, oversight, and predictable delivery for your program.
